1
|
McKaig T, Logan K, Nesbitt H, Callan B, McKeown S, O'Sullivan JM, Kelly P, O'Rourke D, McHale AP, Callan JF. Ultrasound targeted microbubble destruction using docetaxel and Rose Bengal loaded Microbubbles for targeted Chemo-Sonodynamic therapy treatment of prostate cancer. Eur J Pharm Biopharm 2023; 192:196-205. [PMID: 37858804 DOI: 10.1016/j.ejpb.2023.10.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 10/05/2023] [Accepted: 10/16/2023] [Indexed: 10/21/2023]
Abstract
Docetaxel (DTX) chemotherapy is commonly used in the treatment of patients with advanced prostate cancer demonstrating modest improvements in survival. As these patients are often elderly and the chemotherapy treatment is not targeted, it is often poorly tolerated. More targeted approaches that increase therapeutic efficacy yet reduce the amount of toxic chemotherapy administered are needed. In this manuscript, we investigate the potential of ultrasound targeted microbubble destruction (UTMD) to deliver a combination of docetaxel chemotherapy and Rose Bengal mediated sonodynamic therapy (SDT) in pre-clinical prostate cancer models. A Rose Bengal modified phospholipid was synthesized and used as a component lipid to prepare a microbubble (MB) formulation that was also loaded with DTX. The DTX-MB-RB formulation was used in the UTMD mediated treatment of androgen sensitive and androgen resistant 3D spheroid and murine models of prostate cancer. Results from the 3D spheroid experiments showed UTMD mediated DTX-MB-RB chemo-sonodynamic therapy to be significantly more effective at reducing cell viability than UTMD mediated DTX or SDT treatment alone. In an androgen sensitive murine model of prostate cancer, UTMD mediated DTX-MB-RB chemo-sonodynamic therapy was as effective as androgen deprivation therapy (ADT) at controlling tumour growth. However, when both treatments were combined, a significant improvement in tumour growth delay was observed. In an androgen resistant murine model, UTMD mediated DTX-MB-RB chemo-sonodynamic therapy was significantly more effective than standard DTX monotherapy. Indeed, the DTX dose administered using the DTX-MB-RB formulation was 91% less than standard DTX monotherapy. As a result, UTMD mediated DTX-MB-RB treatment was well tolerated while animals treated with DTX monotherapy displayed significant weight loss which was attributed to acute toxic effects. These results highlight the potential of UTMD mediated DTX-MB-RB chemo-sonodynamic therapy as a targeted, well tolerated alternative treatment for advanced prostate cancer.
Collapse
Affiliation(s)
- Thomas McKaig
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Keiran Logan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Heather Nesbitt
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Bridgeen Callan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Stephanie McKeown
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Joe M O'Sullivan
- Patrick G. Johnston Centre for Cancer Research , Queens University of Belfast, Belfast Northern Ireland, BT9 7AE, UK
| | - Paul Kelly
- Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK
| | - Declan O'Rourke
- Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK
| | - Anthony P McHale
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - John F Callan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK.
| |
Collapse
|
2
|
Gao J, Logan KA, Nesbitt H, Callan B, McKaig T, Taylor M, Love M, McHale AP, Griffith DM, Callan JF. A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction. J Control Release 2021; 338:358-366. [PMID: 34481018 DOI: 10.1016/j.jconrel.2021.08.050] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 08/23/2021] [Accepted: 08/30/2021] [Indexed: 01/05/2023]
Abstract
FOLFIRINOX and FOLFOXIRI are combination chemotherapy treatments that incorporate the same drug cocktail (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) but exploit an altered dosing regimen when used in the management of pancreatic and colorectal cancer, respectively. Both have proven effective in extending life when used to treat patients with metastatic disease but are accompanied by significant adverse effects. To facilitate improved tumour-targeting of this drug combination, an ultrasound responsive microbubble formulation loaded with 5-fluorouridine, irinotecan and oxaliplatin (FIRINOX MB) was developed and its efficacy tested, together with the non-toxic folinic acid, in preclinical murine models of pancreatic and colorectal cancer. A significant improvement in tumour growth delay was observed in both models following ultrasound targeted microbubble destruction (UTMD) mediated FIRINOX treatment with pancreatic tumours 189% and colorectal tumours 82% smaller at the conclusion of the study when compared to animals treated with a standard dose of FOLFIRINOX. Survival prospects were also improved for animals in the UTMD mediated FIRINOX treatment group with an average survival of 22.17 ± 12.19 days (pancreatic) and 44.40 ± 3.85 days (colorectal) compared to standard FOLFIRINOX treatment (15.83 ± 4.17 days(pancreatic) and 37.50 ± 7.72 days (colon)). Notably, this improved efficacy was achieved using FIRINOX MB that contained 5-fluorouricil, irinotecan and oxaliplatin loadings that were 13.44-fold, 9.19-fold and 1.53-fold lower than used for the standard FOLFIRINOX treatment. These results suggest that UTMD enhances delivery of FIRINOX chemotherapy, making it significantly more effective at a substantially lower dose. In addition, the reduced systemic levels of 5-fluorouracil, irinotecan and oxaliplatin should also make the treatment more tolerable and reduce the adverse effects often associated with this treatment.
Collapse
Affiliation(s)
- Jinhui Gao
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland BT14 6AB, UK
| | - Keiran A Logan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland BT14 6AB, UK
| | - Heather Nesbitt
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland BT14 6AB, UK
| | - Bridgeen Callan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland BT14 6AB, UK
| | - Thomas McKaig
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland BT14 6AB, UK
| | - Mark Taylor
- Department of HPB Surgery, Mater Hospital, Belfast, Northern Ireland, UK
| | - Mark Love
- Imaging Centre, The Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland BT12 6BA, UK
| | - Anthony P McHale
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland BT14 6AB, UK.
| | - Darren M Griffith
- Department of Chemistry, RCSI, 123 St Stephens Green, Dublin 2, Ireland; SSPC, Synthesis and Solid State Pharmaceutical Centre, Ireland.
| | - John F Callan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland BT14 6AB, UK.
| |
Collapse
|
3
|
Nesbitt H, Logan K, Thomas K, Callan B, Gao J, McKaig T, Taylor M, Love M, Stride E, McHale AP, Callan JF. Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. Cancer Lett 2021; 517:88-95. [PMID: 34119606 DOI: 10.1016/j.canlet.2021.06.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 06/03/2021] [Accepted: 06/07/2021] [Indexed: 02/07/2023]
Abstract
The emergence of immune checkpoint inhibitors (ICI's) in the past decade has proven transformative in the area of immuno-oncology. The PD-1/PD-L1 axis has been particularly well studied and monoclonal antibodies developed to block either the receptor (anti PD-1) or its associated ligand (anti PD-L1) can generate potent anti-tumour immunity in certain tumour models. However, many "immune cold" tumours remain unresponsive to ICI's and strategies to stimulate the adaptive immune system and make these tumours more susceptible to ICI treatment are currently under investigation. Sonodynamic therapy (SDT) is a targeted anti-cancer treatment that uses ultrasound to activate a sensitiser with the resulting generation of reactive oxygen species (ROS) causing direct cell death by apoptosis and necrosis. SDT has also been shown to stimulate the adaptive immune system in a pre-clinical model of colorectal cancer. In this manuscript, we investigate the ability of microbubble mediated SDT to control tumour growth in a bilateral tumour mouse model of pancreatic cancer by treating the target tumour with SDT and observing the effects at the off-target untreated tumour. The results demonstrated a significant 287% decrease in tumour volume when compared to untreated animals 11 days following the initial treatment with SDT, which reduced further to 369% when SDT was combined with anti-PD-L1 ICI treatment. Analysis of residual tumour tissues remaining after treatment revealed increased levels of infiltrating CD4+ and CD8+ T-lymphocytes (respectively 4.65 and 3.16-fold more) in the off-target tumours of animals where the target tumour was treated with SDT and anti-PD-L1, when compared to untreated tumours. These results suggest that SDT treatment elicits an adaptive immune response that is potentiated by the anti-PD-L1 ICI in this particular model of pancreatic cancer.
Collapse
Affiliation(s)
- Heather Nesbitt
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Keiran Logan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Keith Thomas
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Bridgeen Callan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Jinhui Gao
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Thomas McKaig
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - Mark Taylor
- Department of HPB Surgery, Mater Hospital, Belfast, Northern Ireland, BT14 6AB, UK
| | - Mark Love
- Imaging Centre, The Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland, BT12 6BA, UK
| | - Eleanor Stride
- Institute of Biomedical Engineering, University of Oxford, Oxford, OX3 7DQ, UK
| | - Anthony P McHale
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK
| | - John F Callan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine, Northern Ireland, UK.
| |
Collapse
|
4
|
Dhillon SK, Porter SL, Rizk N, Sheng Y, McKaig T, Burnett K, White B, Nesbitt H, Matin RN, McHale AP, Callan B, Callan JF. Rose Bengal–Amphiphilic Peptide Conjugate for Enhanced Photodynamic Therapy of Malignant Melanoma. J Med Chem 2020; 63:1328-1336. [DOI: 10.1021/acs.jmedchem.9b01802] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Simanpreet Kaur Dhillon
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| | - Simon L. Porter
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| | - Nermeen Rizk
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| | - Yingjie Sheng
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| | - Thomas McKaig
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| | - Kathyrn Burnett
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| | - Bronagh White
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| | - Heather Nesbitt
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| | - Rubeta N. Matin
- Department of Dermatology, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, U.K
| | - Anthony P. McHale
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| | - Bridgeen Callan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| | - John F. Callan
- Biomedical Sciences Research Institute, University of Ulster, Coleraine BT52 1SA, Northern Ireland, U.K
| |
Collapse
|
5
|
Logan K, Foglietta F, Nesbitt H, Sheng Y, McKaig T, Kamila S, Gao J, Nomikou N, Callan B, McHale AP, Callan JF. Targeted chemo-sonodynamic therapy treatment of breast tumours using ultrasound responsive microbubbles loaded with paclitaxel, doxorubicin and Rose Bengal. Eur J Pharm Biopharm 2019; 139:224-231. [DOI: 10.1016/j.ejpb.2019.04.003] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Revised: 03/29/2019] [Accepted: 04/02/2019] [Indexed: 01/11/2023]
|